By skyforbes 
$MDGL has the only FDA and EMA approved drug for NASH, a form of fatty liver disease. They have had the drug on the market in the U.S. for almost 2 years. The catalyst driver for this stock is that it will be available in Germany starting in the new year and it will have a country-by-country rollout after it was approved by the EMA in August of 2025. They have a miracle drug. With 3.74M shares shorted and an 8.4 Short Ratio the institutions will struggle to cover. The Short % of float is 18.93% making it relatively high and prone to a short-squeeze if there’s a sharp increase in price. Another flag that signals short squeeze potential is that OVER 105% OF THE STOCK IS OWNED BY INSTITUTIONS BECAUSE THEY ARE LENDING SHARES!
I’m a med student and believe in the drug Rezdiffra. It will help many people and save lives. Institutions are betting on its downfall so big pharma can scoop it up, but I like the stock! None of this is financial advice because I am autistic.